Beta Bionics, Inc. - Common Stock (BBNX)

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 3, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) of the November 3, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW ORLEANS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) --

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) between June 30, 2025 and February 24, 2026, inclusive.What To Do Next:

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026. Beta Bionics describes itself as a “commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes.”

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

The DJS Law Group reminds investors of a class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”).

Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarter 2026 performance.

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company’s growth trends, new patient starts, business outlook, and related operating metrics.

Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.